Interferon profile of the mucosal immunity in women with papillomavirus infection

Markelova, E.V.; Tulupova, M.S.; Nevezhkina, T.A.; Matyushkina, L. S.; Chernikova, M.A.; Кныш, С. В.

doi:10.32364/2587-6821-2022-6-2-67-71

Cited by 1 publication

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Острые респираторные заболевания являются одной из наиболее распространенных групп забо леваний в структуре всех инфекционных и парази тарных болезней в Российской Федерации. Острые респираторные вирусные инфекции (ОРВИ) опре деляют 80-95% всех случаев респираторных за болеваний и характеризуются крайней интенсив ностью распространения в популяции, особенно в сообществах с высокой плотностью населения [1] Согласно данным еженедельного националь ного бюллетеня по гриппу и ОРВИ, за [4].…”

Section: Introductionunclassified

On the Possibility of Using the Topical form of the Recombinant Interferon alpha-2b Drug in the Prevention of Acute Respiratory Viral Infections in Organized Groups

Kostinov,

Markelova,

Knysh

et al. 2024

Epidemiology and Vaccinal Prevention

View full text Add to dashboard Cite

Relevance. Respiratory infections are an urgent problem for organized groups, including military ones, since the transmission of pathogens by airborne droplets and household contact routes, physical and psychological stress on adaptive mechanisms contribute to the development of the epidemic process. There is no doubt that vaccination makes a significant contribution to the prevention of respiratory infections, but the contingent remains vulnerable to other pathogens against which there are no vaccines. Therefore, the search for new methods of non-specific prevention is necessary in maintaining the health of persons permanently residing in collectives. Aim. Evaluation of the possibility of using the topical form of the recombinant interferon α-2b drug for the prevention of acute respiratory viral infections in organized groups. Materials and methods. The work was carried out according to the methodology of a multicenter (3 Centers) double-blind controlled trial involving 3,235 people aged 18 to 22 years, who were divided into three groups: 1 gy. - received a recombinant interferon α-2b (Grippferon) drug 3 drops in each nasal passage 2 times a day in for two weeks; 2 g. - saline solution intranasally according to the same scheme; 3 g. - the volunteers did not receive anything. The frequency of respiratory infections was studied. Results and discussion. Medical monitoring of the study participants, which was carried out for 2 months, showed that in the groups from the Center 1, the incidence of acute respiratory diseases for 2 months in the main group (gr. 1) was 2.3 times lower than in the control (gr. 2) and the comparison group (gr. 3). In the Center 2 The data corresponded to the dynamics of Center 1: the incidence values were 2.4-2.5 times lower in Group 1. In Center 3, the values were 2.0-2.1, respectively. The epidemic effect of intranasal administration of the topical form of the drug recombinant interferon α-2b is due to its effect on the factors of mucosal immunity, which contributes to non-specific protection and increased body resistance against respiratory infections. Conclusions. The presented advantages of the recombinant interferon α-2b drug make it possible to draw attention to the clinical feasibility of its use for preventive purposes in organized groups, including military ones, from the position of high epidemiological effectiveness, both pre-exposure and post-exposure prevention of acute respiratory viral infections.

show abstract

Section: Introductionunclassified